Avanos Medical Stock News

Avanos Medical (AVNS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Avanos Medical Inc (AVNS) shares closed today at 1.8% above its 52 week low of $28.95, giving the company a market cap of $1B. The stock is currently down 16.0% year-to-date, down 37.1% over the past 12 months, and down 23.8% over the past five years. This week, the Dow Jones Industrial Average fell 1.6%, and the S&P 500 fell 3.5%. Trading Activity Trading volume this week was 6.7% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 4.4% lower than its 5-day moving average, 9.8% lower than its 20-day moving average, and 8.9% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 83.6% The company's stock price performance over the past 12 months lags the peer average by 51.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Avanos Medical Inc (AVNS) shares closed today at 0.7% above its 52 week low of $28.95, giving the company a market cap of $1B. The stock is currently down 10.7% year-to-date, down 35.0% over the past 12 months, and down 17.0% over the past five years. This week, the Dow Jones Industrial Average fell 2.5%, and the S&P 500 fell 4.1%. Trading Activity Trading volume this week was 43.0% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 55.6% The company's stock price performance over the past 12 months lags the peer average by 38.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

AGNC, AVNS, and SQ have been added to the Zacks Rank #5 (Strong Sell) List on January 24, 2022

ONEM, ALXO, and AVNS have been added to the Zacks Rank #5 (Strong Sell) List on January 19, 2022

ALPHARETTA, Ga., Jan. 10, 2022 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced that Joe Woody, chief executive officer, will present at the 40th Annual J.P.

Avanos Medical today announced it entered into a definitive agreement to acquire OrthogenRx for $160 million. OrthogenRx currently makes viscosupplementation therapies to treat knee osteoarthritis pain, as well as its commercial hyaluronic acid (HA) therapy products GenVisc 850 and TriVisc. Avanos will purchase the company for $130 million in cash at closing and an additional […] The post Avanos Medical to buy OrthogenRx for $160M appeared first on Drug Delivery Business .

Brokerages predict that Avanos Medical, Inc. (NYSE:AVNS) will announce earnings of $0.40 per share for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Avanos Medicals earnings, with the lowest EPS estimate coming in at $0.39 and the highest estimate coming in at $0.41. Avanos Medical posted earnings per share of []

Avanos Medical's (AVNS) new solution to help healthcare providers with respect to patients' overall pain management process.

Avanos Medical (AVNS) reported earnings 30 days ago. What's next for the stock?

Invesco Ltd. increased its stake in Avanos Medical, Inc. (NYSE:AVNS) by 21.2% in the 2nd quarter, HoldingsChannel reports. The fund owned 335,053 shares of the companys stock after acquiring an additional 58,537 shares during the period. Invesco Ltd.s holdings in Avanos Medical were worth $12,186,000 at the end of the most recent quarter. A number []

Brokerages forecast that Avanos Medical, Inc. (NYSE:AVNS) will post sales of $190.65 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Avanos Medicals earnings, with the lowest sales estimate coming in at $190.60 million and the highest estimate coming in at $190.70 million. Avanos Medical reported sales of []

UBS Asset Management Americas Inc. boosted its stake in Avanos Medical, Inc. (NYSE:AVNS) by 2.0% during the second quarter, Holdings Channel.com reports. The fund owned 47,952 shares of the companys stock after purchasing an additional 923 shares during the quarter. UBS Asset Management Americas Inc.s holdings in Avanos Medical were worth $1,744,000 at the end []